Genmab and BliNK Biomedical Enter into Commercial License Agreement

NEXT STORY
World Biosensors Market Expected to Reach $34.3 Billion by 2025 — Biosensors in Asia-Pacific is Gaining Major Traction
PREV STORY
C-RAD and Elekta sign agreement to distribute C-RAD’s cutting-edge SIGRT solutions in America
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

author_avatar
NASDAQ Market News

Pliant Therapeutics to Participate in Upcoming Virtual Investor Events

author_avatar
NASDAQ Market News

FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.

Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty ...

author_avatar
NASDAQ Market News